Literature DB >> 25590533

Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1.

Michael T Perfetti1, Brandi M Baughman1, Bradley M Dickson1, Yunxiang Mu2, Gaofeng Cui3, Pavel Mader4, Aiping Dong4, Jacqueline L Norris1, Scott B Rothbart5, Brian D Strahl5, Peter J Brown4, William P Janzen1, Cheryl H Arrowsmith4, Georges Mer3, Kevin M McBride2, Lindsey I James1, Stephen V Frye1.   

Abstract

Improving our understanding of the role of chromatin regulators in the initiation, development, and suppression of cancer and other devastating diseases is critical, as they are integral players in regulating DNA integrity and gene expression. Developing small molecule inhibitors for this target class with cellular activity is a crucial step toward elucidating their specific functions. We specifically targeted the DNA damage response protein, 53BP1, which uses its tandem tudor domain to recognize histone H4 dimethylated on lysine 20 (H4K20me2), a modification related to double-strand DNA breaks. Through a cross-screening approach, we identified UNC2170 (1) as a micromolar ligand of 53BP1, which demonstrates at least 17-fold selectivity for 53BP1 as compared to other methyl-lysine (Kme) binding proteins tested. Structural studies revealed that the tert-butyl amine of UNC2170 anchors the compound in the methyl-lysine (Kme) binding pocket of 53BP1, making it competitive with endogenous Kme substrates. X-ray crystallography also demonstrated that UNC2170 binds at the interface of two tudor domains of a 53BP1 dimer. Importantly, this compound functions as a 53BP1 antagonist in cellular lysates and shows cellular activity by suppressing class switch recombination, a process which requires a functional 53BP1 tudor domain. These results demonstrate that UNC2170 is a functionally active, fragment-like ligand for 53BP1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25590533      PMCID: PMC4402254          DOI: 10.1021/cb500956g

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  48 in total

1.  Role of ATM and the damage response mediator proteins 53BP1 and MDC1 in the maintenance of G(2)/M checkpoint arrest.

Authors:  Atsushi Shibata; Olivia Barton; Angela T Noon; Kirsten Dahm; Dorothee Deckbar; Aaron A Goodarzi; Markus Löbrich; Penny A Jeggo
Journal:  Mol Cell Biol       Date:  2010-04-26       Impact factor: 4.272

Review 2.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

3.  Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins.

Authors:  Tim J Wigle; J Martin Herold; Guillermo A Senisterra; Masoud Vedadi; Dmitri B Kireev; Cheryl H Arrowsmith; Stephen V Frye; William P Janzen
Journal:  J Biomol Screen       Date:  2009-12-11

4.  A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.

Authors:  Liu Cao; Xioaling Xu; Samuel F Bunting; Jie Liu; Rui-Hong Wang; Longyue L Cao; J Julie Wu; Tie-Nan Peng; Junjie Chen; Andre Nussenzweig; Chu-Xia Deng; Toren Finkel
Journal:  Mol Cell       Date:  2009-08-28       Impact factor: 17.970

5.  53BP1 regulates DSB repair using Rif1 to control 5' end resection.

Authors:  Michal Zimmermann; Francisca Lottersberger; Sara B Buonomo; Agnel Sfeir; Titia de Lange
Journal:  Science       Date:  2013-01-10       Impact factor: 47.728

6.  53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage.

Authors:  Tamara A Mochan; Monica Venere; Richard A DiTullio; Thanos D Halazonetis
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

7.  Preparation of recombinant peptides with site- and degree-specific lysine (13)C-methylation.

Authors:  Gaofeng Cui; Maria Victoria Botuyan; Georges Mer
Journal:  Biochemistry       Date:  2009-05-12       Impact factor: 3.162

Review 8.  Epigenetic modifications as therapeutic targets.

Authors:  Theresa K Kelly; Daniel D De Carvalho; Peter A Jones
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

9.  53BP1 is required for class switch recombination.

Authors:  Irene M Ward; Bernardo Reina-San-Martin; Alexandru Olaru; Kay Minn; Koji Tamada; Julie S Lau; Marilia Cascalho; Lieping Chen; Andre Nussenzweig; Ferenc Livak; Michel C Nussenzweig; Junjie Chen
Journal:  J Cell Biol       Date:  2004-05-24       Impact factor: 10.539

10.  53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark.

Authors:  Amélie Fradet-Turcotte; Marella D Canny; Cristina Escribano-Díaz; Alexandre Orthwein; Charles C Y Leung; Hao Huang; Marie-Claude Landry; Julianne Kitevski-LeBlanc; Sylvie M Noordermeer; Frank Sicheri; Daniel Durocher
Journal:  Nature       Date:  2013-06-12       Impact factor: 49.962

View more
  15 in total

1.  Developing Spindlin1 small-molecule inhibitors by using protein microarrays.

Authors:  Narkhyun Bae; Monica Viviano; Xiaonan Su; Jie Lv; Donghang Cheng; Cari Sagum; Sabrina Castellano; Xue Bai; Claire Johnson; Mahmoud Ibrahim Khalil; Jianjun Shen; Kaifu Chen; Haitao Li; Gianluca Sbardella; Mark T Bedford
Journal:  Nat Chem Biol       Date:  2017-05-15       Impact factor: 15.040

2.  Selective Inhibition of CBX6: A Methyllysine Reader Protein in the Polycomb Family.

Authors:  Natalia Milosevich; Michael C Gignac; James McFarlane; Chakravarthi Simhadri; Shanti Horvath; Kevin D Daze; Caitlin S Croft; Aman Dheri; Taylor T H Quon; Sarah F Douglas; Jeremy E Wulff; Irina Paci; Fraser Hof
Journal:  ACS Med Chem Lett       Date:  2015-12-07       Impact factor: 4.345

Review 3.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

4.  Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform.

Authors:  Tobias Wagner; Holger Greschik; Teresa Burgahn; Karin Schmidtkunz; Anne-Kathrin Schott; Joel McMillan; Lina Baranauskienė; Yan Xiong; Oleg Fedorov; Jian Jin; Udo Oppermann; Daumantas Matulis; Roland Schüle; Manfred Jung
Journal:  Nucleic Acids Res       Date:  2016-02-17       Impact factor: 16.971

5.  Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.

Authors:  Kimberly D Barnash; Juliana The; Jacqueline L Norris-Drouin; Stephanie H Cholensky; Beau M Worley; Fengling Li; Jacob I Stuckey; Peter J Brown; Masoud Vedadi; Cheryl H Arrowsmith; Stephen V Frye; Lindsey I James
Journal:  ACS Comb Sci       Date:  2017-02-22       Impact factor: 3.784

Review 6.  Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.

Authors:  Nilesh Zaware; Ming-Ming Zhou
Journal:  Curr Opin Chem Biol       Date:  2017-07-06       Impact factor: 8.822

7.  Structure-Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains.

Authors:  Jacob I Stuckey; Catherine Simpson; Jacqueline L Norris-Drouin; Stephanie H Cholensky; Junghyun Lee; Ryan Pasca; Nancy Cheng; Bradley M Dickson; Kenneth H Pearce; Stephen V Frye; Lindsey I James
Journal:  J Med Chem       Date:  2016-09-19       Impact factor: 7.446

Review 8.  Chemical probes for methyl lysine reader domains.

Authors:  Lindsey I James; Stephen V Frye
Journal:  Curr Opin Chem Biol       Date:  2016-06-25       Impact factor: 8.822

Review 9.  The Chemical Biology of Reversible Lysine Post-translational Modifications.

Authors:  Zhipeng A Wang; Philip A Cole
Journal:  Cell Chem Biol       Date:  2020-07-21       Impact factor: 8.116

Review 10.  Using Chemical Epigenetics to Target Cancer.

Authors:  Virangika K Wimalasena; Tingjian Wang; Logan H Sigua; Adam D Durbin; Jun Qi
Journal:  Mol Cell       Date:  2020-05-13       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.